Log in

NASDAQ:SESN - Sesen Bio Stock Price, Forecast & News

$0.85
0.00 (0.00 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$0.83
Now: $0.85
$0.87
50-Day Range
$0.84
MA: $0.95
$1.03
52-Week Range
$0.80
Now: $0.85
$2.60
Volume627,482 shs
Average Volume823,405 shs
Market Capitalization$89.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SESN
CUSIPN/A
CIKN/A
Phone617-444-8550

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$430,000.00
Book Value$0.57 per share

Profitability

Net Income$-33,690,000.00

Miscellaneous

Employees24
Market Cap$89.10 million
Next Earnings Date3/2/2020 (Estimated)
OptionableOptionable

Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter.


Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

How were Sesen Bio's earnings last quarter?

Sesen Bio Inc (NASDAQ:SESN) posted its earnings results on Tuesday, November, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. View Sesen Bio's Earnings History.

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Sesen Bio.

What price target have analysts set for SESN?

2 analysts have issued 1 year price targets for Sesen Bio's stock. Their forecasts range from $2.25 to $2.25. On average, they anticipate Sesen Bio's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 164.3% from the stock's current price. View Analyst Price Targets for Sesen Bio.

What is the consensus analysts' recommendation for Sesen Bio?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sesen Bio.

What are Wall Street analysts saying about Sesen Bio stock?

Here are some recent quotes from research analysts about Sesen Bio stock:
  • 1. According to Zacks Investment Research, "Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven Biotherapeutics, is based in Massachusetts, United States. " (1/15/2020)
  • 2. HC Wainwright analysts commented, "We maintain our Neutral rating of SESN and our 12-month price target of $1.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected Vicinium and Proxinium revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate. We derive an rNPV of $45M for the products and add in cash and cash equivalents of $42M to arrive at a 12-month price target of $0.77 per diluted share, which we round to $1.00. (1) clinical; (2) regulatory; (3) commercial; (4) financial; and (5) intellectual property." (5/14/2019)

Has Sesen Bio been receiving favorable news coverage?

News stories about SESN stock have been trending very positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sesen Bio earned a coverage optimism score of 3.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Sesen Bio.

Are investors shorting Sesen Bio?

Sesen Bio saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 3,930,000 shares, an increase of 12.6% from the January 15th total of 3,490,000 shares. Based on an average daily trading volume, of 1,696,900 shares, the days-to-cover ratio is presently 2.3 days. Approximately 4.1% of the shares of the company are sold short. View Sesen Bio's Current Options Chain.

Who are some of Sesen Bio's key competitors?

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include XOMA (XOMA), Advanced Micro Devices (AMD), Amarin (AMRN), Agile Therapeutics (AGRX), AVEO Pharmaceuticals (AVEO), Verastem (VSTM), Exelixis (EXEL), Anavex Life Sciences (AVXL), Clovis Oncology (CLVS) and Crispr Therapeutics (CRSP).

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the folowing people:
  • Mr. Richard F. Fitzgerald, CFO, Sec. & Treasurer (Age 55)
  • Dr. Thomas R. Cannell, Pres, CEO & Director (Age 57)
  • Dr. K. Christopher Garcia, Co-Founder & Member of Scientific Advisory Board
  • Dr. Gregory L. Verdine, Co-Founder (Age 60)
  • Dr. Casey T. Weaver, Co-Founder & Member of Scientific Advisory Board

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.69%), Credit Suisse AG (0.24%), Virtu Financial LLC (0.19%), Oxford Asset Management LLP (0.16%) and Private Advisor Group LLC (0.03%).

Which institutional investors are buying Sesen Bio stock?

SESN stock was bought by a variety of institutional investors in the last quarter, including Credit Suisse AG, Oxford Asset Management LLP, Virtu Financial LLC, Geode Capital Management LLC and Private Advisor Group LLC.

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $0.85.

How big of a company is Sesen Bio?

Sesen Bio has a market capitalization of $89.10 million and generates $430,000.00 in revenue each year. The company earns $-33,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Sesen Bio employs 24 workers across the globe.View Additional Information About Sesen Bio.

What is Sesen Bio's official website?

The official website for Sesen Bio is http://www.sesenbio.com/.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-444-8550 or via email at [email protected]


MarketBeat Community Rating for Sesen Bio (NASDAQ SESN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Sesen Bio and other stocks. Vote "Outperform" if you believe SESN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SESN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel